Psoriatic Arthritis Treatment Market Size, Share, Future Trends, Growth, and Industry Forecast 2034
Psoriatic Arthritis Treatment Market Size, Share, Future Trends, Growth, and Industry Forecast 2034
The psoriatic arthritis treatment market size in 2026 comprises medicines used to manage the symptoms and progression of this inflammatory condition. Treatment options include conventional disease-modifying antirheumatic drugs, biologic therapies, targeted synthetic medicines, and other medications used to address pain and inflammation. The selection of treatment depends on disease severity, affected joints, previous treatment response, and individual patient requirements. Growing awareness of the condition and developments in immunology are contributing to the expansion of available therapeutic options.
According to Fortune Business Insights, the global psoriatic arthritis treatment market size was valued at USD 12.59 billion in 2025 and is projected to grow from USD 13.97 billion in 2026 to USD 32.11 billion by 2034, exhibiting a CAGR of 10.96% during the forecast period. North America dominated the psoriatic arthritis treatment market with a market share of 43.78% in 2025. Psoriatic arthritis is a chronic inflammatory condition associated with psoriasis that can affect joints, tendons, and surrounding tissues. Treatment aims to control inflammation, reduce pain and stiffness, manage disease activity, and help prevent long-term joint damage.
Major companies operating in the global psoriatic arthritis treatment market include:
F. Hoffmann-La Roche Ltd (Basel, Switzerland)
Novartis AG (Basel, Switzerland)
Amgen (California, United States)
Pfizer Inc. (New York, United States)
Johnson & Johnson Services, Inc. (New Jersey, United States)
Eli Lilly and Company (Indiana, United States)
AstraZeneca (Cambridge, United Kingdom)
Sanofi (Paris, France)
Bristol-Myers Squibb Company (New York, United States)
GlaxoSmithKline plc. (Brentford, United Kingdom)
Bayer AG (Leverkusen, Germany)
Increasing Diagnosis and Demand for Long-Term Disease Management
Growing recognition of psoriatic arthritis and its relationship with psoriasis is supporting demand for treatment. The condition can involve joint pain, swelling, stiffness, and inflammation in other parts of the musculoskeletal system. Improved awareness among patients and healthcare professionals can encourage earlier medical evaluation and help patients access appropriate treatment. Since psoriatic arthritis is a chronic condition, many patients require ongoing monitoring and treatment adjustments, contributing to sustained demand for medicines.
Development of Biologic and Targeted Therapies
Advances in biologic medicines and targeted synthetic therapies are creating new opportunities in the market. These treatments act on specific immune system pathways associated with inflammation. Tumor necrosis factor inhibitors and medicines targeting interleukin pathways are among the therapeutic approaches used in psoriatic arthritis management. Continued research into disease mechanisms and treatment responses is encouraging pharmaceutical companies to develop therapies for patients with different clinical needs.
High Treatment Costs and Access Limitations
The cost of advanced medicines remains a challenge for the market. Biologic and targeted therapies can involve substantial treatment expenses, which may restrict access for patients in regions with limited insurance coverage or reimbursement support. Differences in healthcare infrastructure and the availability of rheumatology specialists can also influence diagnosis and treatment adoption. In addition, treatment selection requires consideration of safety profiles, patient characteristics, and possible adverse effects.
The global psoriatic arthritis treatment market includes established pharmaceutical companies with expertise in immunology, inflammation, and specialty medicines. Competition is influenced by clinical efficacy, safety profiles, treatment convenience, regulatory approvals, pricing, and access to healthcare markets. Companies are investing in research and development to strengthen their therapeutic portfolios and address unmet treatment needs.
Biologic medicines and targeted therapies remain important areas of product development. Manufacturers are exploring different mechanisms of action and treatment approaches to serve patients with varying disease characteristics and responses to existing medicines. Clinical trials, product approvals, strategic collaborations, and geographical expansion are among the activities that can influence competitive positioning. Companies with strong research capabilities and established distribution networks are important participants in the evolving treatment landscape.
The psoriatic arthritis treatment market can be
By Drugs Class (Non-steroidal Anti-inflammatory Drugs (NSAIDS), Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Others)
By Route of Administration (Oral, Parenteral, and Topical)
By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/industry-reports/psoriatic-arthritis-treatment-market-101066
North America
North America dominated the global psoriatic arthritis treatment market with a share of 43.78% in 2025. The region benefits from established healthcare infrastructure, access to advanced medicines, and the presence of major pharmaceutical companies. Awareness of inflammatory conditions and access to specialist care support diagnosis and treatment. The availability of biologic and targeted therapies also contributes to the region's market position.
Europe
Europe represents an important market, supported by established healthcare systems, specialist medical services, and access to advanced pharmaceutical products. Research activities and the presence of major pharmaceutical manufacturers contribute to treatment innovation. Reimbursement policies, medicine availability, and differences in healthcare systems across countries influence regional market development.
Asia Pacific
Asia Pacific offers growth opportunities through improvements in healthcare infrastructure, increasing awareness of inflammatory diseases, and expanding access to specialty medicines. Growing healthcare investments and the development of pharmaceutical distribution networks can support treatment availability. Diagnosis rates, affordability, and access to rheumatology specialists remain important factors influencing market development.
The future of the psoriatic arthritis treatment market will be shaped by continued innovation in immunology, the development of targeted therapies, and improvements in long-term disease management. Pharmaceutical companies are expected to focus on treatments that address different inflammatory pathways and provide additional options for patients who do not respond adequately to existing medicines. Clinical research and new drug development will remain important to the industry's progress.
Earlier diagnosis, improved access to specialist care, and growing awareness of treatment options may further influence market demand. Advances in personalized treatment approaches could also support more individualized disease management. Companies investing in research, clinical development, and broader access to innovative medicines will be important participants as the global psoriatic arthritis treatment market advances toward 2034.
Curious About Japan’s Market? Explore the Latest -Psoriatic Arthritis Treatment Market- Insights